Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MEWA Launches the First Saudi Water Week Next April to Shape the Future of the Water Sector Regionally and Globally28.2.2026 12:55:00 CET | Press release
MEWA Launches the First Saudi Water Week Next April RIYADH, SA / ACCESS Newswire / February 28, 2026 / The Ministry of Environment, Water and Agriculture will inaugurate the first Saudi Water Week during the second week of April. This premier national and international forum will convene policymakers, specialists, researchers, private sector entities, and relevant water sector organizations from both within Saudi Arabia and internationally. This initiative underscores the Ministry's sustained commitment to bolstering water security, reinforcing the sustainable governance of water resources, and fostering scientific research and innovation within this critical sector. The Ministry clarified that the Saudi Water Week will feature several specialized events, including the Arab Water Forum and the Second Stakeholders Meeting for the World Water Forum 2027, in addition to detailed presentations of the achievements of the water sector in the Kingdom and other national sectors. The organizati
Assembly Hires Three Industry Leaders in Europe to Accelerate Growth27.2.2026 12:00:00 CET | Press release
Northway, Ayre, and Panchal add senior depth across AI and data strategy, programmatic activation, and client leadership as Assembly scales in Europe LONDON, UK / ACCESS Newswire / February 27, 2026 / Assembly enters 2026 with momentum and the leadership to match. The Stagwell media agency appoints James Northway as EVP, Global Head of AI and Data Strategy; David Ayre as Europe Head of Programmatic; and Bav Panchal as Europe Managing Partner, strengthening its bench across decision intelligence, activation, and client leadership. Assembly is building on its momentum in the region, following the recent Jabra win and the appointment of Bridget Hopkins as CEO of Europe. These strategic hires accelerate Assembly's expansion across Europe as clients push for integrated brand performance solutions that connect data, technology, media, and commerce to drive measurable growth. Assembly is meeting that demand through continued investment in its STAGE AI Experience Engine and Brand Performance P
Innodata Reports Fourth Quarter and Full Year 2025 Results26.2.2026 22:05:00 CET | Press release
48% Full-Year Revenue Growth and Strong Q4 Results Anticipates ~35%+ Revenue Growth in 2026 with Expanding Customer Diversification Announces Innovations in Dataset Creation and Evaluations for LLMs, AI Agents, and Physical AI (Robotics) NEW YORK CITY, NY / ACCESS Newswire / February 26, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the fourth quarter and the year ended December 31, 2025. Revenue of $72.4 million for the three months ended December 31, 2025, representing 22% year-over-year organic revenue growth. Revenue of $251.7 million for the year ended December 31, 2025, representing 48% year-over-year organic revenue growth. Adjusted EBITDA of $15.7 million for the three months ended December 31, 2025, an increase of $1.6 million, or 11%, from $14.1 million in the same period last year.* Adjusted EBITDA of $57.9 million for the year ended December 31, 2025, an increase of $23.3 million, or 68%, from $34.6 million in the same period last year.* Net income of $8.8 m
Loar Holdings Inc. Reports Q4 2025 and Full Year 2025 Record Results, and Upward Revisions to Full Year 2026 Outlook26.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / February 26, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the fourth quarter and full year of 2025 and upward revisions to the full year 2026 outlook. "As we close the year, I am pleased to report that Loar once again delivered record results across key financial metrics, including Net Sales, Adjusted EBITDA, and Adjusted EBITDA Margin," said Dirkson Charles, Loar CEO and Executive Co‑Chairman of the Board of Directors. "Driven by favorable end‑market dynamics and disciplined execution across the organization, our team delivered strong operating performance while advancing our long‑term value creation strategy. These results underscore the scalability and resilience of our business model and reinforce Loar's position as a leading aerospace and defense component supplier. We also successfully completed the acquisitions of LMB Fans & Motors and Harper Engineering, further strengthening
U.S. Polo Assn. Returns as Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup for Third Consecutive Year26.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND DUBAI, UAE / ACCESS Newswire / February 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly served as the Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup, held January 28 through February 14 at the renowned Al Habtoor Polo Club in Dubai, United Arab Emirates.Dubai Wolves by Thera with their trophy on stage at the Dubai Polo Gold Cup 2026 at the Al Habtoor Polo Club Photo Credit: Margarita Crotto Now marking its third consecutive year supporting the prestigious tournament, U.S. Polo Assn. provided custom performance jerseys to participating teams, apparel for event staff, and exclusive player prizes for the finalists. Spectators joined in the excitement during the traditional divot stomp with a special U.S. Polo Assn. cap giveaway, adding a spirited fan moment to the two-week competition in the UAE. The 2026 Dubai Polo Gold Cup Final delivered an electrifying showdown of world-renowned pl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom